Drug Profile


Alternative Names: Ro 42-1611; RO 421611

Latest Information Update: 16 Aug 2006

Price : $50

At a glance

  • Originator Roche
  • Class Antimalarials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Falciparum malaria

Most Recent Events

  • 14 Sep 2000 Profile reviewed but no significant changes made
  • 25 Sep 1997 Phase-III clinical trials for Falciparum malaria in Gabon (PO)
  • 25 Sep 1997 Phase-II clinical trials for Falciparum malaria in Nigeria (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top